140462-76-6 | Olopatadine HCl

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
50mg	98%	in stock	$22.00	$15.00
250mg	98%	in stock	$29.00	$20.00
1g	98%	in stock	$56.00	$39.00
5g	98%	in stock	$195.00	$136.00
10g	98%	in stock	$341.00	$239.00
25g	98%	in stock	$667.00	$467.00

Description

• Catalog Number: AA62640
• Chemical Name: Olopatadine HCl
• CAS Number: 140462-76-6
• Molecular Formula: C21H24ClNO3
• Molecular Weight: 373.8732
• MDL Number: MFCD00875716
• SMILES: CN(CC/C=C/1c2cc(ccc2OCc2c1cccc2)CC(=O)O)C.Cl

Computed Properties

• Complexity: 488
• Covalently-Bonded Unit Count: 2
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5

Upstream Synthesis Route

(Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride is a versatile compound widely used in chemical synthesis. It serves as a crucial intermediate in the development of various pharmaceuticals and agrochemicals. The unique structure of this compound allows it to participate in diverse chemical reactions, such as condensation, nucleophilic addition, and ring-closing reactions. In organic synthesis, it acts as a key building block for creating complex molecular structures with specific pharmacological or biological activities. Its application in the field of medicinal chemistry involves the preparation of potential drug candidates targeting various diseases. Through its involvement in synthetic methodologies, (Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride enables the efficient and scalable production of valuable compounds with tailored properties.

Literature

• Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis.

  Experimental dermatology 20120901

• [A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan].

  Nippon Ganka Gakkai zasshi 20120901

• The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice.

  Allergy 20120801

• Stereoselective syntheses of the antihistaminic drug olopatadine and its E-isomer.

  The Journal of organic chemistry 20120720

• Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

  Clinical therapeutics 20120601

• Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.

  Archives of dermatological research 20120501

• The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats.

  Biological & pharmaceutical bulletin 20120101

• Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis.

  Expert opinion on drug metabolism & toxicology 20111201

• Thermal angiooedema induced by hot water.

  Acta dermato-venereologica 20110501

• Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.

  American journal of ophthalmology 20110401

• A rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of olopatadine concentration in human plasma.

  Journal of analytical toxicology 20110301

• Intrastromal corneal ring segments for bilateral keratoconus in an 11-year-old boy.

  Journal of cataract and refractive surgery 20110101

• Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.

  Drug design, development and therapy 20110101

• Olopatadine hydrochloride inhibits capsaicin-induced flare response in humans.

  Pharmacology 20110101

• Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.

  Allergy and asthma proceedings 20110101

• Comprehensive report of olopatadine 0.6% nasal spray as treatment for children with seasonal allergic rhinitis.

  Allergy and asthma proceedings 20110101

• Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis.

  American journal of rhinology & allergy 20110101

• Olopatadine suppresses the late phase reaction in parthenium dermatitis.

  Indian journal of dermatology, venereology and leprology 20110101

• Stability-indicating high-performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydrochloride in tablet dosage form.

  Journal of AOAC International 20110101

• Dermatitis induced by estrogen and progesterone: dual positive results on the intradermal skin test.

  Dermatitis : contact, atopic, occupational, drug 20110101

• Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis.

  Current medical research and opinion 20100701

• Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.

  Eye & contact lens 20100701

• Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older.

  Expert opinion on pharmacotherapy 20100601

• Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.

  Expert opinion on pharmacotherapy 20100401

• Olopatadine nasal spray for the treatment of allergic rhinitis.

  Expert review of clinical immunology 20100301

• Histamine stimulates interleukin-6 production through histamine H1 receptors in human amnion cells.

  Gynecologic and obstetric investigation 20100101

• Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis.

  Allergy and asthma proceedings 20100101

• Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.

  European journal of ophthalmology 20100101

• [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].

  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101

• Comprehensive review of olopatadine: the molecule and its clinical entities.

  Allergy and asthma proceedings 20100101

• Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice.

  International archives of allergy and immunology 20100101

• Synergetic effects of prednisolone and olopatadine on atopic dermatitis model of hairless mice.

  Pharmacology 20100101

• Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study.

  Allergy and asthma proceedings 20100101

• Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.

  The Journal of dermatology 20091201

• Olopatadine hydrochloride inhibits scratching behavior induced by a proteinase-activated receptor 2 agonist in mice.

  Journal of dermatological science 20091101

• Azelastine and olopatadine in the treatment of allergic rhinitis.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20091101

• Multiple action agents and the eye: do they really stabilize mast cells?

  Current opinion in allergy and clinical immunology 20091001

• Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.

  Acta ophthalmologica 20090801

• Cerebral histamine H1 receptor binding potential measured with PET under a test dose of olopatadine, an antihistamine, is reduced after repeated administration of olopatadine.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090601

• Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride.

  The Journal of dermatology 20090401

• Drug approvals: '08 in review. Olopatadine hydrochloride (Patanase) nasal spray.

  The Nurse practitioner 20090201

• Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.

  Journal of dermatological science 20090101

• Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.

  Clinical therapeutics 20090101

• Is conjunctival allergen challenge a model of seasonal rhinoconjunctivitis?

  Allergy and asthma proceedings 20090101

• Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.

  Clinical drug investigation 20090101

• Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.

  Allergy and asthma proceedings 20090101

• Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

  BMC ophthalmology 20090101

• Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.

  Journal of investigational allergology & clinical immunology 20090101

• Efficacy of repeated pretreatment with olopatadine hydrochloride on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.

  Pharmacology 20090101

• Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis.

  Allergy and asthma proceedings 20090101

• [Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis].

  Oftalmologia (Bucharest, Romania : 1990) 20090101

• [Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis].

  Revista medica del Instituto Mexicano del Seguro Social 20090101

• Comparison of the conjunctival toxicity of topical ocular antiallergic agents.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081201

• Repeated pre-treatment with antihistamines suppresses [corrected] transcriptional up-regulations of histamine H(1) receptor and interleukin-4 genes in toluene-2,4-diisocyanate-sensitized rats.

  Journal of pharmacological sciences 20081201

• Effects of olopatadine in limited scleroderma with peripheral eosinophils.

  Geriatrics & gerontology international 20080901

• Evaluation of the antihistamine effects of olopatadine, cetirizine and fexofenadine during a 24 h period: a double-blind, randomized, crossover, placebo-controlled comparison in skin responses induced by histamine iontophoresis.

  Archives of dermatological research 20080701

• The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20080701

• Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.

  International immunopharmacology 20080601

• Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.

  Experimental eye research 20080501

• Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.

  Expert opinion on drug metabolism & toxicology 20080401

• Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.

  Methods and findings in experimental and clinical pharmacology 20080401

• Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.

  Current medical research and opinion 20080201

• Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function.

  Pharmacology 20080101

• The noncompetitive antagonism of histamine H1 receptors expressed in Chinese hamster ovary cells by olopatadine hydrochloride: its potency and molecular mechanism.

  Pharmacology 20080101

• P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.

  Drug metabolism and pharmacokinetics 20080101

• Enhancement of basophil apoptosis by olopatadine and theophylline.

  Allergy and asthma proceedings 20080101

• A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.

  Allergy and asthma proceedings 20080101

• Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%.

  Allergy and asthma proceedings 20080101

• Use of olopatadine ophthalmic solution and reactivity of histamine skin testing.

  Allergy and asthma proceedings 20080101

• An assessment of the onset and duration of action of olopatadine nasal spray.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20071201

• Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.

  Current eye research 20071201

• Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20071101

• [Pharmacological profile and clinical efficacy of olopatadine hydrochloride ophthalmic solution (Patanol 0.1% ophthalmic solution)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070901

• Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801

• Safety and tolerability of olopatadine 0.2% in children and adolescents.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801

• The effect of H1 antagonists carebastine and olopatadine on histamine induced expression of CC chemokines in cultured human nasal epithelial cells.

  Allergology international : official journal of the Japanese Society of Allergology 20070601

• Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.

  Current medical research and opinion 20070601

• Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice.

  The British journal of dermatology 20070501

• Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070201

• Inhibition of cytokine-induced expression of T-cell cytokines by antihistamines.

  Journal of investigational allergology & clinical immunology 20070101

• Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.

  Allergy and asthma proceedings 20070101

• Chronic red eyes. Diagnosis: allergic conjunctivitis due to airborne allergen.

  Comprehensive ophthalmology update 20070101

• Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.

  Allergy and asthma proceedings 20070101

• Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.

  Advances in therapy 20070101

• Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.

  Allergy and asthma proceedings 20070101

• Olopatadine attenuates the enhancement of capsaicin-evoked substance P release by bradykinin from cultured dorsal root ganglion neurons.

  European journal of pharmacology 20061215

• Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.

  Eye & contact lens 20061201

• Neuronal conditions of spinal cord in dermatitis are improved by olopatadine.

  European journal of pharmacology 20061010

• [Clinical effects of olopatadine hydrochloride on pruritus in skin diseases].

  Arerugi = [Allergy] 20061001

• Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.

  Clinical therapeutics 20061001

• [The use of 'Antigrippin-maximum' in the complex therapy of patients with acute respiratory diseases].

  Voenno-meditsinskii zhurnal 20061001

• [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].

  Orvosi hetilap 20060910

• Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.

  Current medical research and opinion 20060901

• Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment.

  Investigative ophthalmology & visual science 20060801

• [Misleading advertisement on Opatanol].

  Nederlands tijdschrift voor geneeskunde 20060701

• Pharmacotherapy of allergic eye disease.

  Expert opinion on pharmacotherapy 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Red, itchy eyes, giant papillae.

  Advance for nurse practitioners 20060301

• Role of substance P in allergic nasal symptoms in rats.

  European journal of pharmacology 20060217

• Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.

  Acta ophthalmologica Scandinavica 20060201

• Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.

  British journal of clinical pharmacology 20060101

• Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.

  Mediators of inflammation 20060101

• Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo.

  Allergy and asthma proceedings 20060101

• [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].

  Arquivos brasileiros de oftalmologia 20060101

• Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice.

  Pharmacology 20051201

• Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051201

• The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice.

  European journal of pharmacology 20051107

• Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051101

• Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20051001

• Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20051001

• The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis.

  The Journal of dermatology 20051001

• Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.

  Current medical research and opinion 20050901

• Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.

  Clinical therapeutics 20050901

• Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.

  Current medical research and opinion 20050501

• A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.

  Clinical therapeutics 20050501

• Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.

  Ocular immunology and inflammation 20050201

• [Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis].

  Arerugi = [Allergy] 20050201

• Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050101

• Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.

  The Journal of dermatology 20050101

• Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis.

  Journal of dermatological science 20041201

• Effects of olopatadine hydrochloride, an antihistamine drug, on skin inflammation induced by repeated topical application of oxazolone in mice.

  The British journal of dermatology 20041201

• Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.

  Current medical research and opinion 20041201

• A review of olopatadine for the treatment of ocular allergy.

  Expert opinion on pharmacotherapy 20040901

• Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance.

  Clinical and experimental dermatology 20040901

• Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.

  Current medical research and opinion 20040801

• Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.

  Current medical research and opinion 20040801

• Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.

  Clinical therapeutics 20040801

• Ocular allergy treatment comparisons: azelastine and olopatadine.

  Current allergy and asthma reports 20040701

• A review of the use of olopatadine in allergic conjunctivitis.

  International ophthalmology 20040501

• Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells.

  Biochemical pharmacology 20040401

• [Olopatadine].

  Revue de l'infirmiere 20040401

• The promotion of eosinophil degranulation and adhesion to conjunctival epithelial cells by IgE-activated conjunctival mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20040101

• Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.

  Allergy and asthma proceedings 20040101

• Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.

  Arzneimittel-Forschung 20040101

• Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers.

  Human psychopharmacology 20031201

• Interactions of olopatadine and selected antihistamines with model and natural membranes.

  Ocular immunology and inflammation 20031201

• Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.

  Clinical therapeutics 20031001

• Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.

  Acta ophthalmologica Scandinavica 20030801

• Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.

  Clinical therapeutics 20030801

• [Opatanol].

  Ugeskrift for laeger 20030721

• One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.

  Clinical therapeutics 20030701

• Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells.

  Cellular immunology 20030701

• Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.

  Eye & contact lens 20030401

• [In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].

  Journal francais d'ophtalmologie 20030401

• Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.

  International archives of allergy and immunology 20030301

• A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.

  Clinical therapeutics 20030301

• Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort.

  Advances in therapy 20030101

• Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.

  Clinical therapeutics 20021001

• Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.

  Clinical therapeutics 20020901

• Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study.

  Clinical therapeutics 20020801

• Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.

  Clinical therapeutics 20020701

• Occupational allergy caused by Peruvian lily (Alstroemeria).

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020601

• Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.

  Clinical therapeutics 20020601

• Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020501

• Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.

  Biochemical and biophysical research communications 20020412

• Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.

  Japanese journal of pharmacology 20020401

• Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils.

  Japanese journal of pharmacology 20020401

• Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.

  Allergy and asthma proceedings 20020101

• Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20011101

• Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats.

  Japanese journal of pharmacology 20011001

• Mucus fishing syndrome: case report and new treatment option.

  Optometry (St. Louis, Mo.) 20011001

• Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.

  Clinical therapeutics 20010801

• [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010701

• Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010601

• [Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010601

• Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs.

  Japanese journal of pharmacology 20010601

• Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs.

  Japanese journal of pharmacology 20010401

• Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201

• The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 19960101